Cabel's Recent Posts
Title Rating Company Posted on ▲
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk? 2 Resverlogix Corp. Jul 06, 2019 05:38AM
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits 2 Resverlogix Corp. Jul 08, 2019 09:11AM
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits Resverlogix Corp. Jul 08, 2019 12:49PM
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits 3 Resverlogix Corp. Jul 08, 2019 04:27PM
How does it work,... MACE after April 18, 2019 1 Resverlogix Corp. Jul 09, 2019 07:37AM
Re: Patient Years & MACE rate Question 1 Resverlogix Corp. Jul 11, 2019 09:16AM
Re: Patient Years & MACE rate Question 3 Resverlogix Corp. Jul 11, 2019 10:15AM
Re: I am asking myself.... 6 Resverlogix Corp. Jul 11, 2019 07:51PM
Re: Insider Selling 2 Resverlogix Corp. Jul 12, 2019 08:28AM
Re: New Apabetalone Publication in Clinical Epigenetics 3 Resverlogix Corp. Jul 12, 2019 05:58PM
Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics 2 Resverlogix Corp. Jul 15, 2019 06:53PM
Re: EASD 2019 Sept 16-20, 2019 1 Resverlogix Corp. Jul 19, 2019 10:00AM
Re: Contest Tally - Cut Off Tonight 9 pm EST 1 Resverlogix Corp. Jul 23, 2019 03:00AM
Re: Contest Tally - Cut Off Tonight 9 pm EST 3 Resverlogix Corp. Jul 23, 2019 08:25AM
One week Monday.... 2 Resverlogix Corp. Jul 26, 2019 10:33AM
Re: Zacks SCR 8/5/19: Targeting September Readout for BETonMACE 1 Resverlogix Corp. Aug 05, 2019 01:26PM
Re: Possible news releases for Resverlogix based on Amarin/ESC/AHA 4 Resverlogix Corp. Aug 07, 2019 02:59PM
Re: ALP Levels Predict Adverse Cardiovascular Outcomes And Cognitive Impairment In High Risk Patients 1 Resverlogix Corp. Aug 08, 2019 01:44PM
Re: If we follow AMRN's pattern... 1 Resverlogix Corp. Aug 09, 2019 05:27PM
Re: If we follow AMRN's pattern... 2 Resverlogix Corp. Aug 09, 2019 09:28PM